RFG Advisory LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

RFG Advisory LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 9,006 shares of the company’s stock after purchasing an additional 635 shares during the period. RFG Advisory LLC’s holdings in Eli Lilly and Company were worth $7,979,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of LLY. Swedbank AB bought a new position in Eli Lilly and Company in the first quarter worth about $932,797,000. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after buying an additional 1,133,810 shares during the last quarter. Wulff Hansen & CO. raised its stake in shares of Eli Lilly and Company by 90,438.0% during the 2nd quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after acquiring an additional 936,033 shares in the last quarter. GQG Partners LLC lifted its position in Eli Lilly and Company by 20.2% during the first quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after acquiring an additional 648,094 shares during the last quarter. Finally, Comerica Bank boosted its stake in Eli Lilly and Company by 71.6% in the second quarter. Comerica Bank now owns 1,512,983 shares of the company’s stock valued at $1,369,825,000 after acquiring an additional 631,312 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Citigroup assumed coverage on Eli Lilly and Company in a report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research report on Thursday. They issued an “outperform” rating and a $1,100.00 price objective for the company. Finally, Bank of America boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $986.00.

Eli Lilly and Company Stock Up 0.1 %

Eli Lilly and Company stock opened at $917.86 on Friday. The business’s 50-day moving average price is $921.21 and its 200 day moving average price is $857.37. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The firm has a market cap of $872.34 billion, a price-to-earnings ratio of 135.18, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.